Translational balance

Different mindsets, motives and mandates have blocked the progress of companies and academics in forming deals to move discoveries from academia to industry. The solution is a balancing act that engages scientists in the partnerships, imposes a realistic view of the risk and, if necessary, trades value for the ability to execute.

Those were the conclusions of a panel of leaders from translational centers across Europe and the U.S. that met last month at the BIO-Europe conference to discuss issues surrounding the commercialization of therapeutics and diagnostics from universities and other academic organizations. The conference was organized by EBD Group and the Biotechnology Industry Organization (BIO)...